Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD80 (B7-1) and CD86 (B7-2) are co-stimulatory molecules expressed on antigen-presenting cells (APCs). They interact with CD28 on T cells to provide a crucial secondary signal for T cell activation, proliferation, and differentiation. These molecules also interact with CTLA4, an inhibitory receptor, to regulate immune responses and maintain tolerance. Targeting CD80/CD86-CD28 interactions is a strategy in cancer immunotherapy and autoimmune disease treatment.
CD80 and CD86 bind to CD28 on T cells to provide a co-stimulatory signal, leading to T cell activation, proliferation, and cytokine production. They also bind to CTLA4, an inhibitory receptor, to dampen T cell responses.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell co-stimulatory molecules CD80 and CD86 (CD80/CD86).